1242157-15-8

Basic information

• Product Name: 6-Bromo-8-fluoro-3,4-dihydroisoquinolin-1(2H)-one
• Synonyms: 6-Bromo-8-fluoro-3,4-dihydroisoquinolin-1(2H)-one
• CAS NO: 1242157-15-8
• Molecular Formula: C9H7BrFNO
• Molecular Weight: 244.0603832
• Mol File: 1242157-15-8.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 6-Bromo-8-fluoro-3,4-dihydroisoquinolin-1(2H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromo-8-fluoro-3,4-dihydroisoquinolin-1(2H)-one(1242157-15-8)
• EPA Substance Registry System: 6-Bromo-8-fluoro-3,4-dihydroisoquinolin-1(2H)-one(1242157-15-8)

Safety Data

• Hazardous Substances Data: 1242157-15-8(Hazardous Substances Data)

Usage

General Description

6-bromo-8-fluoro-3,4-dihydroisoquinolin-1(2H)-one is a chemical compound with the molecular formula C9H7BrFNO. It is a derivative of isoquinoline, a heterocyclic compound with a fused benzene and pyridine ring system. 6-bromo-8-fluoro-3,4-dihydroisoquinolin-1(2H)-one is a fluoro-substituted isoquinolinone, which may have potential applications in medicinal chemistry and pharmaceutical research. The presence of bromine and fluorine atoms on the isoquinoline ring can potentially modulate the compound's physicochemical and pharmacological properties, making it useful in drug design and discovery. More research is needed to fully understand the potential uses and properties of 6-bromo-8-fluoro-3,4-dihydroisoquinolin-1(2H)-one.

Upstream product

• 395639-63-1 1-(4-bromo-2-fluorophenyl)-3-chloro-propan-1-one 
• 151982-51-3 4-bromo-2-fluorobenzoyl chloride 
• 112704-79-7 2-fluoro-4-bromobenzoic acid 
• 1242157-14-7 5-bromo-7-fluoro-2,3-dihydro-1H-inden-1-one 

Downstream Products

• 1242156-23-5 6-cyclopropyl-8-fluoro-2-(2-hydroxymethyl-3-{1-methyl-5-[5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-2H-isoquinolin-1-one 
• 1242156-55-3 2-(3-chloro-2-(hydroxymethyl)phenyl)-6-cyclopropyl-8-fluoroisoquinoline-1(2H)-one 
• 1242156-54-2 2-chloro-6-(6-cyclopropyl-8-fluoro-1-oxoisoquinolin-2 (1H)-yl)benzaldehyde 
• 1242156-53-1 6-cyclopropyl-8-fluoro-1-oxoisoquinoline-2-(1H)-one 
• 1242157-65-8 6-cyclopropyl-2-(3-{5-[5-(4-ethylpiperazin-1-yl)pyridin-2-ylamino]-1-methyl-6-oxo-1,6-dihydropyridin-3-yl}-2-hydroxymethylphenyl)-8-fluoro-2H-isoquinolin-1-one 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AS DIHYDROOROTATE DEHYDROGENASE INHIBITORS

Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Embodiments of such compounds are represented by Formula (I) and Formula (II) as follows: and wherein R1, R2, R3, R4, R5, R6, R7, R8, X1, X2, X3, X4, Y and Z, are defined herein.

Structure-based drug design of RN486, a potent and selective Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis

Structure-based drug design was used to guide the optimization of a series of selective BTK inhibitors as potential treatments for Rheumatoid arthritis. Highlights include the introduction of a benzyl alcohol group and a fluorine substitution, each of which resulted in over 10-fold increase in activity. Concurrent optimization of drug-like properties led to compound 1 (RN486) (J. Pharmacol. Exp. Ther. 2012, 341, 90), which was selected for advanced preclinical characterization based on its favorable properties.